Skip to content

A study of vitamin K2-7 in Osteoporosis

An open labelled trial to study the safety and efficacy of Vitamin K2-7 in Human Osteoporosis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024684
Enrollment
30
Registered
2020-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M818- Other osteoporosis without currentpathological fracture

Interventions

Intervention1: Vitamin K2-7: 100 mcg capsule twice a day after lunch and dinner for 30 days Control Intervention1: NA: NA

Sponsors

SSV Phytopharmaceuticals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Men and non-pregnant women who are at least 20 years and under 75 years of age; and 2.The osteoporosis diagnosed by standard DXA measurement (BMD T-score: - 2.5 or below); and 3.Pain defined by a level of greater than or equal to 4 on Visual Analogue Scale (VAS). 4. Patients who are, in the opinion of the Investigator, able to comply with the requirements of the study; and 5.Patients who have been adequately informed of the nature and risks of the study and who have given written informed consent prior to receiving study medication.

Exclusion criteria

Exclusion criteria: 1.Women who are pregnant, as determined by a urine pregnancy test, or breast-feeding. 2.Presence or history of congestive heart failure (NYHA class III/IV) within the prior 12 weeks. 3.Recent myocardial infarction (within the prior 12 weeks). 4.Unstable angina pectoris. 5.Known or suspected renal insufficiency defined as creatinine >1.5mg/dl. 6.Known or suspected hepatic insufficiency defined as abnormal liver function tests (GOT/GPT) >3x upper normal limit (i.e., 120 U/l). 7.Known hypomotility syndrome: (such as hypothyroidism or scleroderma). 8.Recent major trauma within the prior 12 weeks. 9.Recent surgery requiring anesthesia including coronary artery bypass graft (within 12 weeks). 10.Recent hospitalization (within 12 weeks)

Design outcomes

Primary

MeasureTime frame
Reduction in Pain Score on the basis of Visual Analog Scale (VAS)Timepoint: 30 days

Secondary

MeasureTime frame
Safety and EfficacyTimepoint: 30 days

Countries

India

Contacts

Public ContactDr Akhil Chaudhari

Vakratund Hospital

akhil.vakratund@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026